ReviewExperimental & molecular medicine2026
Integrative structural and dynamics studies of epidermal growth factor receptor (EGFR).
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The epidermal growth factor receptor (EGFR) is one of the most extensively studied targets in cancer therapy, yet its complex regulatory mechanisms remain partially understood. While traditional structural approaches have provided invaluable insights, the static crystal structures of individual domains have been limited to capturing the full dynamic nature of EGFR regulation. Understanding the complete structure of full-length EGFR has been challenging due to the inherent flexibility and complexity of the multidomain membrane protein. Here we integrate recent structural studies using cryo-electron microscopy, molecular dynamics simulations and single-molecule biophysics. Integrated knowledge has revealed that EGFR samples multiple transient conformational states of monomer and higher-order oligomers, and that activation requires coordinated structural transitions between the extracellular domain, transmembrane helix, juxtamembrane region and asymmetric kinase dimer. The allosteric coupling and oligomerization propensity of EGFR are altered by oncogenic mutations, membrane environments and ligand binding. Strategies that incorporate conformational dynamics, allosteric regulation and static structures of EGFR may yield inhibitors with improved selectivity and reduced resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.